Your browser is no longer supported. Please, upgrade your browser.
GT Biopharma, Inc.
Index- P/E- EPS (ttm)-9.40 Insider Own0.80% Shs Outstand28.39M Perf Week27.09%
Market Cap387.47M Forward P/E- EPS next Y-1.01 Insider Trans0.00% Shs Float19.46M Perf Month57.05%
Income-28.30M PEG- EPS next Q-0.24 Inst Own8.00% Short Float6.26% Perf Quarter96.34%
Sales- P/S- EPS this Y43.50% Inst Trans- Short Ratio1.86 Perf Half Y355.92%
Book/sh-12.29 P/B- EPS next Y-3.10% ROA- Target Price23.00 Perf Year526.89%
Cash/sh0.20 P/C73.11 EPS next 5Y- ROE105.80% 52W Range2.04 - 14.33 Perf YTD106.99%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High4.12% Beta0.30
Dividend %- Quick Ratio0.20 Sales past 5Y- Gross Margin- 52W Low630.76% ATR1.27
Employees3 Current Ratio0.20 Sales Q/Q- Oper. Margin- RSI (14)80.21 Volatility12.30% 13.47%
OptionableNo Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume1.31 Prev Close13.20
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume656.38K Price14.92
Recom2.00 SMA2039.58% SMA5088.45% SMA200176.31% Volume844,171 Change13.03%
Apr-13-21Initiated B. Riley Securities Buy $21
Mar-17-21Initiated ROTH Capital Buy $25
Apr-26-21 07:00AM  
Apr-19-21 07:00AM  
Apr-12-21 08:00AM  
Apr-08-21 08:00AM  
Mar-29-21 07:00AM  
Mar-17-21 08:00AM  
Mar-10-21 08:00AM  
Mar-08-21 08:30AM  
Mar-04-21 08:30AM  
Mar-02-21 03:00AM  
Feb-18-21 08:00AM  
Feb-16-21 08:00AM  
Feb-11-21 08:00AM  
Jan-19-21 09:00AM  
Jan-12-21 10:00AM  
Jan-04-21 09:45AM  
Dec-28-20 09:35AM  
Dec-21-20 11:00AM  
Dec-17-20 09:15AM  
Dec-14-20 09:05AM  
Dec-08-20 07:30AM  
Nov-18-20 07:30AM  
Nov-12-20 07:30AM  
Oct-15-20 07:45AM  
Oct-13-20 07:45AM  
Sep-22-20 07:45AM  
Aug-20-20 08:00AM  
Aug-04-20 08:00AM  
GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. The company develops various immuno-oncology product candidates, including GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I/II clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and other CD33+ hematopoietic malignancies; GTB-C3550, a follow-on to its lead candidates TriKE, GTB-3550; GTB-4550, a single-chain tri-specific single chain variable fragments (scFv) recombinant fusion protein conjugate for the treatment of PD-L1+ solid tumor cancers; and GTB-5550, a single-chain tri-specific scFv recombinant fusion protein conjugate for the treatment of B7H3+ solid tumor cancers. GT Biopharma, Inc. has a co-development partnership agreement with Altor BioScience Corporation for the clinical development of a 161533 TriKE fusion protein for cancer therapies; a license agreement with the Regents of the University of Minnesota to develop and commercialize cancer therapies using TriKE technology; and a collaboration agreement with Cytovance Biologics to provide development services for a TriKE therapeutic for the treatment of coronavirus infection. The company was formerly known as OXIS International, Inc. and changed its name to GT Biopharma, Inc. in July 2017. GT Biopharma, Inc. was incorporated in 1965 and is based in Beverly Hills, California.